The company's authorisation and allotment committee approved the opening of the issue on 6 July 2026.

The floor price of Rs 531.70 is at a discount of 5.64% to the scrip’s previous closing price of Rs 563.50 on the BSE.

The company may offer a discount of not more than 5% on the floor price so calculated for the issue. The issue price will be determined in consultation with the bookrunning lead managers appointed for the issue.

Blue Jet Healthcare is a speciality pharmaceutical and healthcare ingredient company and an end-to-end integrated Contract Development and Manufacturing Organisation (CDMO).

On a standalone basis, the company reported a net profit of Rs 64.34 crore in Q4 FY26, down 41.56% year-on-year (YoY) but up 60.17% quarter-on-quarter (QoQ). Revenue from operations declined 31.07% YoY to Rs 234.67 crore in Q4 FY26 due to negligible sales of one molecule in the PI vertical. However, revenue increased 21.96% QoQ from Rs 192.41 crore, driven by higher sales of advanced contrast media.